September 20, 2016
Eisai is intent on seeking new indications for its antiepileptic drug Fycompa (perampanel). The drug, seen as the company’s next flagship, is currently under development as a monotherapy and for a refractory type of epilepsy called Lennox-Gastaut syndrome (LGS). With...read more